Novavax And J&J's COVID-19 Vaccines Report Encouraging Phase Three Trials Results; Both Have Tie-Ups With Indian Vaccine Makers
Novavax, J&J Covid-19 Vaccines Show Encouraging Results In Phase 3 TrialsCovid-19 vaccine - representative image (Twitter)

In a positive development, United States (US) based pharmaceutical majors Novavax and Johnson & Johnson (J&J) have announced the encouraging results of the phase three trials of their respective COVID-19 vaccines, reports Economic Times.

While Novavax's NVX-CoV2373 vaccine has demonstrated a 90 per cent efficacy in the trials conducted in the United Kingdom (UK), J&J's single-dosage vaccine has demonstrated an overall efficacy of 66 per cent, and 85 per cent efficacy in preventing deaths (severe disease) across all age and ethnic groups.

Speaking about Novavax's vaccine, Clive Dix, the chair of UK Vaccine Taskforce said, "The efficacy shown against the emerging variants is also extremely encouraging." He added, "This is an incredible achievement that will ensure we can protect individuals in the UK and the rest of the world from this virus."

Meanwhile, it should be noted that both, Novavax and J&J have also tied up with Indian vaccine manufacturers to produce and supply their vaccines. While Novavax has tied up with Pune based Serum Institute of India (SII), J&J has tied up with Hyderabad based Biological E.

Serum Institute's chief Adar Poonawalla took to Twitter to share that the company has applied for starting trials of the Novavax vaccine in India and that he expects to launch the vaccine in country by June 2021.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber